The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/6626/Demir-Filiz-2021.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2021Author
Kara Polat, AsudeTopal, İlteriş Oğuz
Karadağ, Ayşe Serap
Aksoy, Hasan
Koku Aksu, Ayşe Esra
Özkur, Ezgi
Özkök Akbulut, Tuğba
Topaloğlu Demir, Filiz
Engin, Burhan
Uzunçakmak, Tuğba Kevser
Kıvanç Altunay, İlknur
Metadata
Show full item recordCitation
Kara Polat, A., Topal, İ. O., Karadağ, A. S., Aksoy, H., Koku Aksu, A. E., Özkur, E. ... Kıvanç Altunay, İ. (2021). The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatologic Therapy, 34(1). https://dx.doi.org/10.1111/dth.14691Abstract
There is widespread concern about treatment of psoriasis in COVID-19 pandemic. We aimed to evaluate the epidemiological data, clinical characteristics, treatment features of the psoriasis patients during the pandemic period. We conducted a study in dermatology clinics of seven different tertiary centers. All adult psoriasis patients who were followed up between 11 March 2020 and 28 June 2020, were phone called or questioned in their visit to their follow-up clinics. A semistructured questionnaire was applied and patients' demographics and disease characteristics were recorded. Of 1322 patients, 52.4% were male, and 47.6% were female. According to the questionnaire responses, 964 (72.9%) of these patients could not communicate with their physician during this period, remained 358 (27.1%) patients contacted the physician by phone, email, or hospital visit. From the patients diagnosed as probable/confirmed COVID-19, 14 were female, and 9 were male. Nine of 23 (39.1%) patients were using biologic treatment. There was no statistically significant difference in terms of hospitalization from COVID-19 between the patients using biologics (n = 9) and those who did not (n = 14) (P = 1.00). No mortality was observed among them. Obesity, smoking, age, and accompanying psoriatic arthritis were not among the risk factors affecting the frequency of COVID-19. We only encountered an increased risk in diabetic patients. Also, an exacerbation of psoriasis was observed with the infection. No difference was found in patients with psoriasis in terms of COVID-19 infection in patients who use biologics and those who don't.
WoS Q Kategorisi
Q3xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q2Source
Dermatologic TherapyVolume
34Issue
1Collections
- Makale Koleksiyonu [3801]
- PubMed İndeksli Yayınlar Koleksiyonu [4264]
- Scopus İndeksli Yayınlar Koleksiyonu [6620]
- WoS İndeksli Yayınlar Koleksiyonu [6696]